NASDAQ:CEMI Chembio Diagnostics - CEMI Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Chembio Diagnostics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $0.35 0.00 (0.00%) (As of 01/27/2023 12:00 AM ET) Add Compare Share Share Today's Range$0.33▼$0.3850-Day Range$0.20▼$0.3952-Week Range$0.19▼$1.24Volume511,759 shsAverage Volume614,859 shsMarket Capitalization$12.85 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media About Chembio Diagnostics (NASDAQ:CEMI) StockChembio Diagnostics, Inc. engages in the developing, manufacturing, marketing, and licensing of rapid medical tests. It offers rapid point-of-care tests for infectious, tropical and fever, and respiratory diseases, handheld analyzers, and veterinary products. The firm distributes its products to hospitals and clinics, physician offices, clinical laboratories, public health organizations, government agencies, and consumers. The company was founded in 1985 and is headquartered in Hauppauge, NY.Read More Receive CEMI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Chembio Diagnostics and its competitors with MarketBeat's FREE daily newsletter. Email Address CEMI Stock News HeadlinesJanuary 26, 2023 | americanbankingnews.comStockNews.com Initiates Coverage on Chembio Diagnostics (NASDAQ:CEMI)January 21, 2023 | seekingalpha.comCEMI Chembio Diagnostics, Inc.January 28, 2023 | Porter & Company (Ad)Is This The End of Capitalism?EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…January 18, 2023 | americanbankingnews.comChembio Diagnostics (NASDAQ:CEMI) Earns Hold Rating from Analysts at StockNews.comJanuary 7, 2023 | forbes.comChembio DiagnosticsNovember 28, 2022 | finance.yahoo.comChembio Announces FDA CLIA Waiver Submission for DPP HIV-Syphilis SystemNovember 6, 2022 | seekingalpha.comChembio Diagnostics, Inc. (CEMI) Q3 2022 Earnings Call TranscriptNovember 3, 2022 | finance.yahoo.comChembio Diagnostics Reports Third Quarter 2022 Financial ResultsJanuary 28, 2023 | Porter & Company (Ad)The Next Big Crisis Is HereYou just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.October 20, 2022 | finance.yahoo.comChembio Diagnostics to Report Third Quarter 2022 Financial Results on November 3, 2022September 6, 2022 | finance.yahoo.comChembio Diagnostics Awarded $3.2 Million Contract from the CDC for Development and Clinical Validation of Dual-Path Platform Syphilis Screen & Confirm AssaySeptember 3, 2022 | finance.yahoo.comIs Monkeypox Outbreak Cooling? Health Officials Says Virus Transmission Has SlowedAugust 16, 2022 | finance.yahoo.comRapid Test For Monkeypox? NY-Based Chembio Diagnostics Thinks They Can Pull It OffAugust 16, 2022 | finance.yahoo.comChembio Diagnostics Evaluates Monkeypox Rapid Point-of-Care Test DevelopmentAugust 4, 2022 | finance.yahoo.comChembio Diagnostics Reports Second Quarter 2022 Financial ResultsJuly 21, 2022 | finance.yahoo.comChembio Diagnostics to Report Second Quarter 2022 Financial Results on August 4, 2022June 15, 2022 | baystreet.caChembio Expands DistributionJune 15, 2022 | finance.yahoo.comChembio Diagnostics Announces Expansion of Direct-to-Consumer Commercial ChannelMay 17, 2022 | seekingalpha.comChembio's inks contract for HIV test to be made by Reszon Diagnostics at Malaysia facilityMay 17, 2022 | finance.yahoo.comChembio Diagnostics Announces Agreement for Reszon Diagnostics International to Manufacture Chembio’s HIV 1/2 STAT-PAK Assay at Chembio Diagnostics Malaysia FacilityMay 8, 2022 | seekingalpha.comChembio Diagnostics, Inc. (CEMI) CEO Rick Eberly on Q1 2022 Results - Earnings Call TranscriptMay 5, 2022 | finance.yahoo.comChembio Diagnostics Reports First Quarter 2022 Financial ResultsMay 4, 2022 | seekingalpha.comChembio Diagnostics Q1 2022 Earnings PreviewApril 21, 2022 | finance.yahoo.comChembio Diagnostics to Report First Quarter 2022 Financial Results on May 5, 2022March 4, 2022 | benzinga.comWhy Chembio Diagnostics Shares Are FallingMarch 3, 2022 | finance.yahoo.comChembio Diagnostics Reports Fourth Quarter and Full Year 2021 Financial ResultsMarch 3, 2022 | seekingalpha.comChembio Diagnostics Q4 2021 Earnings PreviewSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive CEMI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Chembio Diagnostics and its competitors with MarketBeat's FREE daily newsletter. Email Address CEMI Company Calendar Last Earnings11/03/2022Today1/28/2023Next Earnings (Estimated)3/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CEMI CUSIPN/A CIK1092662 Webwww.chembio.com Phone(631) 924-1135Fax631-924-2065Employees337Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.20) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-33,900,000.00 Net Margins-60.93% Pretax Margin-60.91% Return on Equity-129.14% Return on Assets-50.01% Debt Debt-to-Equity Ratio0.01 Current Ratio1.22 Quick Ratio1.00 Sales & Book Value Annual Sales$47.82 million Price / Sales0.27 Cash FlowN/A Price / Cash FlowN/A Book Value$1.14 per share Price / Book0.31Miscellaneous Outstanding Shares36,710,000Free Float35,497,000Market Cap$12.85 million OptionableNot Optionable Beta1.70 Key ExecutivesRichard L. EberlyPresident, Chief Executive Officer & DirectorPaul J. AngelicoChief Operations Officer & Executive VPLawrence J. SteenvoordenChief Financial Officer, Secretary & Executive VPJavan EsfandiariExecutive VP, Chief Science & Technology OfficerPaul LambotteVice President-Research & DevelopmentKey CompetitorsTrevenaNASDAQ:TRVNDiffusion PharmaceuticalsNASDAQ:DFFNLiminal BioSciencesNASDAQ:LMNLAptevo TherapeuticsNASDAQ:APVOAgile TherapeuticsNASDAQ:AGRXView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 457,450 shares on 11/15/2022Ownership: 4.255%Renaissance Technologies LLCBought 90,100 shares on 11/14/2022Ownership: 0.309%Group One Trading L.P.Bought 100 shares on 11/9/2022Ownership: 0.000%Signaturefd LLCBought 34,300 shares on 11/8/2022Ownership: 0.189%View All Institutional Transactions CEMI Stock - Frequently Asked Questions Should I buy or sell Chembio Diagnostics stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Chembio Diagnostics in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" CEMI shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CEMI, but not buy additional shares or sell existing shares. View CEMI analyst ratings or view top-rated stocks. How have CEMI shares performed in 2023? Chembio Diagnostics' stock was trading at $0.2197 at the start of the year. Since then, CEMI shares have increased by 59.4% and is now trading at $0.3501. View the best growth stocks for 2023 here. Are investors shorting Chembio Diagnostics? Chembio Diagnostics saw a decrease in short interest in the month of January. As of January 15th, there was short interest totaling 1,580,000 shares, a decrease of 20.2% from the December 31st total of 1,980,000 shares. Based on an average trading volume of 412,400 shares, the days-to-cover ratio is presently 3.8 days. View Chembio Diagnostics' Short Interest. When is Chembio Diagnostics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 2nd 2023. View our CEMI earnings forecast. How were Chembio Diagnostics' earnings last quarter? Chembio Diagnostics, Inc. (NASDAQ:CEMI) announced its earnings results on Thursday, November, 3rd. The company reported ($0.21) earnings per share (EPS) for the quarter. The business had revenue of $11.20 million for the quarter. Chembio Diagnostics had a negative net margin of 60.93% and a negative trailing twelve-month return on equity of 129.14%. What other stocks do shareholders of Chembio Diagnostics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Chembio Diagnostics investors own include Prospect Capital (PSEC), Calumet Specialty Products Partners (CLMT), Two Harbors Investment (TWO), BlackRock Capital Investment (BKCC), NovoCure (NVCR), Viper Energy Partners (VNOM), Summit Midstream Partners (SMLP), Washington Prime Group (WPG), Roper Technologies (ROP) and ReWalk Robotics (RWLK). What is Chembio Diagnostics' stock symbol? Chembio Diagnostics trades on the NASDAQ under the ticker symbol "CEMI." How do I buy shares of Chembio Diagnostics? Shares of CEMI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Chembio Diagnostics' stock price today? One share of CEMI stock can currently be purchased for approximately $0.35. How much money does Chembio Diagnostics make? Chembio Diagnostics (NASDAQ:CEMI) has a market capitalization of $12.85 million and generates $47.82 million in revenue each year. The company earns $-33,900,000.00 in net income (profit) each year or ($1.20) on an earnings per share basis. How many employees does Chembio Diagnostics have? The company employs 337 workers across the globe. How can I contact Chembio Diagnostics? Chembio Diagnostics' mailing address is 555 WIRELESS BLVD., HAUPPAUGE NY, 11788. The official website for the company is www.chembio.com. The company can be reached via phone at (631) 924-1135, via email at investor@chembio.com, or via fax at 631-924-2065. This page (NASDAQ:CEMI) was last updated on 1/28/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.